Groupement Hospitalier Edouard Herriot - Emergency Psychiatry Department
Lyon, 69003, France
NCT Number: NCT03045016
After a traumatic event such as an accident or an assault, victims may experience intense stress symptoms that may evolve into "post-traumatic stress disorder" (PTSD). It is a frequent and serious pathology, which can be complicated by depression, addiction or suicide. Few means are available to prevent PTSD in people who have just undergone trauma. Prazosin is an antihypertensive drug that blocks α1 adrenaline receptors which could help to stop the vicious circle of stress and prevent the development of the disease. The objective of this study is to demonstrate the efficacy of prazosin to prevent PTSD in patients who visit an emergency department after trauma.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 2
Lyon, 69003, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients will take Prazosin during 28 days ; there are two periods of treatment (escalation of doses):
Time frame: 6 months
The Presence of PTSD diagnosis will be assessed by the Clinician Administered PTSD Scale (CAPS)
Time frame: 14 days
These symptoms are assessed by Diagnostic and Statistical Manual of Mental Disorders (DSM V) criteria
Time frame: 7 days
This will be investigated using a self questionnaire about frequent side effects due to Prazosin, measurement of blood pressure, and orthostatic hypotension test
Time frame: 14 days
This will be investigated using a self questionnaire about frequent side effects due to Prazosin, measurement of blood pressure, and orthostatic hypotension test
Time frame: 1 month
This will be investigated using a self questionnaire about frequent side effects due to Prazosin, measurement of blood pressure, and orthostatic hypotension test
Time frame: 6 months
Complications of PTSD are attempted suicide, suicidal ideation, addiction, depression and quality of life.
Time frame: 1 month
Compliance will be evaluated by counting the tablets consumed and not consumed at the end of the treatment by Prazosin
Hospices Civils de Lyon
Other
Preliminary Study About the Efficacy of an α1 Blocker (Prazosin) in Preventing the Occurrence of Post-traumatic Stress Disorder (PTSD) in Patients With Acute Stress
Acronym: PRAZOSTRESS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07656545
Acute Stress Disorder, Burns
Los Angeles, California, United States
View Trial DetailsNCT05427708
Acute Stress Disorder, Adjustment Disorder With Anxious Mood
Austin, Texas, United States
View Trial DetailsNCT06502106
Acute Stress Disorder, Mental Disorders
Malmö, Sweden
View Trial DetailsNCT06318195
Acute Stress Disorder, Mental Disorders
Stockholm, Sweden
View Trial Details